Galmed Pharmaceuticals (GLMD) files 6-K on Aramchol Meglumine -001 study results

Rhea-AI Filing Summary

Galmed Pharmaceuticals Ltd. submitted a report for foreign private issuers indicating that it furnished a press release dated November 18, 2025. The release is titled “Galmed Announces Meaningful Top Line Results from -001 Study of Aramchol Meglumine” and is attached as Exhibit 99.1.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the Month of November 2025

001-36345

(Commission File Number)

GALMED PHARMACEUTICALS LTD.

(Exact name of Registrant as specified in its charter)

c/o Meitar Law Offices Abba Hillel Silver Rd.,

Ramat Gan, 5250608

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

On November 18, 2025, Galmed Pharmaceuticals Ltd. issued a press release entitled “Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine.” A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

EXHIBIT INDEX

Exhibit No.		Description
99.1		Press Release, dated November 18, 2025.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Galmed Pharmaceuticals Ltd.
Date: November 18, 2025	By:	/s/ Allen Baharaff
		Allen Baharaff
		President and Chief Executive Officer

FAQ

What did Galmed Pharmaceuticals (GLMD) disclose in this 6-K filing?

Galmed Pharmaceuticals disclosed that it furnished a press release dated November 18, 2025, as part of this 6-K. The release, attached as Exhibit 99.1, reports meaningful top line results from the -001 study of Aramchol Meglumine.

What is the title of Galmed Pharmaceuticals’ November 18, 2025 press release?

The press release is titled “Galmed Announces Meaningful Top Line Results from -001 Study of Aramchol Meglumine.” It is incorporated by reference in the 6-K and attached as Exhibit 99.1 for investors to review in full.

Which SEC form does Galmed Pharmaceuticals (GLMD) use for annual reports?

Galmed Pharmaceuticals indicates that it files its annual reports under cover of Form 20-F. This classification reflects its status as a foreign private issuer reporting under U.S. securities regulations for foreign-based companies.

Who signed the November 2025 Galmed Pharmaceuticals 6-K report?

The 6-K report was signed on behalf of Galmed Pharmaceuticals Ltd. by Allen Baharaff. He is identified in the document as the company’s President and Chief Executive Officer as of the November 18, 2025 signature date.

What exhibit is included with the Galmed Pharmaceuticals November 2025 6-K?

The filing includes Exhibit 99.1, described as a press release dated November 18, 2025. This exhibit contains the detailed announcement of meaningful top line results from the -001 study of Aramchol Meglumine.